Immunovant to Present at the UBS Global Healthcare Conference on May 23rd

Rhea-AI Summary

Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will participate in a fireside chat at the UBS Global Healthcare Conference from May 23-25, 2022.

The chat is scheduled for May 23 at 1:15 PM ET and will be accessible via webcast on the company's website. Immunovant is dedicated to developing therapies for autoimmune diseases, focusing on its investigational compound, batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor.

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference, taking place May 23^rd-25^th, 2022.

UBS Global Healthcare Conference fireside chat details:

Date:		Monday, May 23rd, 2022
Time:		1:15pm Eastern Time
Webcast:		The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.

Contact:

Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com

FAQ

When is Immunovant's CEO participating in the UBS Global Healthcare Conference?

Immunovant's CEO, Pete Salzmann, will participate in the UBS Global Healthcare Conference on May 23, 2022.

What time is the fireside chat with Immunovant's CEO?

The fireside chat is scheduled for 1:15 PM Eastern Time on May 23, 2022.

How can I watch the Immunovant fireside chat?

The presentation will be available via webcast on Immunovant's Investor Relations section of their website.

What is the focus of Immunovant as mentioned in the press release?

Immunovant focuses on developing therapies for autoimmune diseases, particularly through their investigational compound batoclimab.

What is batoclimab and its significance for Immunovant?

Batoclimab is Immunovant's investigational compound, a fully human monoclonal antibody targeting the neonatal Fc receptor, aimed at treating autoimmune diseases.